FDA posed a sprawling set of questions for two-day gene therapy hearing. Here's what companies and experts will be watching for
Gene therapy is having a moment. Once confined to academic labs and a couple of companies, the field now encompasses hundreds of trials, dozens of companies and billions of investment dollars.
With greater power, though, comes greater responsibility. The FDA is asking a panel of outside experts to try and define those responsibilities as they debate a lengthy list of 15 questions Thursday and Friday, in a two-day marathon meeting on the future of a field that has promised one-time treatments for some of the most famous and fatal diseases known to medicine.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.